Search research articles
Contact Us
Filters
Showing results (1-10 of 21) with videos related to
Page
of 3
Sort By:
Bailliere'S Clinical Haematology
|
March 14, 1998
Plasma and metabolic abnormalities in Gaucher's disease
J M Aerts, C E Hollak
Journal of Inherited Metabolic Disease
|
January 5, 2002
Clinically relevant therapeutic endpoints in type I Gaucher disease
C E Hollak, M Maas, J M Aerts
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|
November 21, 2007
Alglucerase: practical guidance on appropriate dosage and administration in patients with Gaucher disease
C E Hollak, J M Aerts, M H van Oers
Journal of Internal Medicine
|
June 1, 1991
Bilateral adrenal tumours in primary aldosteronism: localization of a unilateral aldosteronoma by dexamethasone suppression scan
C E Hollak, M F Prummel, M M Tiel-van Buul
Blood Cells, Molecules & Diseases
|
August 1, 1997
Elevated levels of M-CSF, sCD14 and IL8 in type 1 Gaucher disease
C E Hollak, L Evers, J M Aerts, et al.
The Journal of Clinical Investigation
|
March 1, 1994
Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease
C E Hollak, S van Weely, M H van Oers, et al.
The Netherlands Journal of Medicine
|
August 1, 1990
Thrombocytopenic purpura as first manifestation of human immunodeficiency virus type I (HIV-1) infection
C E Hollak, M J Kersten, J van der Lelie, et al.
British Journal of Haematology
|
March 1, 1997
Coagulation abnormalities in type 1 Gaucher disease are due to low-grade activation and can be partly restored by enzyme supplementation therapy
C E Hollak, M Levi, F Berends, et al.
Growth, Development, and Aging : GDA
|
January 1, 1988
Application of methods used in survival analysis to growth and nutritional studies
W J Hoogendijk, C E Hollak, F M Griffioen, et al.
Blood
|
August 15, 1993
Home treatment with intravenous enzyme replacement therapy for Gaucher disease: an international collaborative study of 33 patients
A Zimran, C E Hollak, A Abrahamov, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 21) with videos related to
Sort By:
Page
of 3
Bailliere'S Clinical Haematology
|
March 14, 1998
Plasma and metabolic abnormalities in Gaucher's disease
J M Aerts, C E Hollak
Journal of Inherited Metabolic Disease
|
January 5, 2002
Clinically relevant therapeutic endpoints in type I Gaucher disease
C E Hollak, M Maas, J M Aerts
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|
November 21, 2007
Alglucerase: practical guidance on appropriate dosage and administration in patients with Gaucher disease
C E Hollak, J M Aerts, M H van Oers
Journal of Internal Medicine
|
June 1, 1991
Bilateral adrenal tumours in primary aldosteronism: localization of a unilateral aldosteronoma by dexamethasone suppression scan
C E Hollak, M F Prummel, M M Tiel-van Buul
Blood Cells, Molecules & Diseases
|
August 1, 1997
Elevated levels of M-CSF, sCD14 and IL8 in type 1 Gaucher disease
C E Hollak, L Evers, J M Aerts, et al.
The Journal of Clinical Investigation
|
March 1, 1994
Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease
C E Hollak, S van Weely, M H van Oers, et al.
The Netherlands Journal of Medicine
|
August 1, 1990
Thrombocytopenic purpura as first manifestation of human immunodeficiency virus type I (HIV-1) infection
C E Hollak, M J Kersten, J van der Lelie, et al.
British Journal of Haematology
|
March 1, 1997
Coagulation abnormalities in type 1 Gaucher disease are due to low-grade activation and can be partly restored by enzyme supplementation therapy
C E Hollak, M Levi, F Berends, et al.
Growth, Development, and Aging : GDA
|
January 1, 1988
Application of methods used in survival analysis to growth and nutritional studies
W J Hoogendijk, C E Hollak, F M Griffioen, et al.
Blood
|
August 15, 1993
Home treatment with intravenous enzyme replacement therapy for Gaucher disease: an international collaborative study of 33 patients
A Zimran, C E Hollak, A Abrahamov, et al.
Page
of 3